Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Non Operating Income: 2019-2025

Historic Non Operating Income for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$41.3 million.

  • BridgeBio Pharma's Non Operating Income fell 250.14% to -$41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$194.1 million, marking a year-over-year decrease of 297.92%. This contributed to the annual value of $50.8 million for FY2024, which is 210.68% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Non Operating Income stood at -$41.3 million, which was up 12.87% from -$47.4 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Non Operating Income high stood at $100.0 million for Q2 2024, and its period low was -$65.2 million during Q1 2025.
  • Over the past 3 years, BridgeBio Pharma's median Non Operating Income value was -$21.8 million (recorded in 2023), while the average stood at -$13.5 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Non Operating Income skyrocketed by 1,063.11% in 2022, and later tumbled by 667.28% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Non Operating Income (Quarterly) stood at $59.0 million in 2021, then crashed by 119.22% to -$11.3 million in 2022, then soared by 162.52% to $7.1 million in 2023, then slumped by 667.28% to -$40.2 million in 2024, then crashed by 250.14% to -$41.3 million in 2025.
  • Its last three reported values are -$41.3 million in Q3 2025, -$47.4 million for Q2 2025, and -$65.2 million during Q1 2025.